909
Views
2
CrossRef citations to date
0
Altmetric
CLINICAL TRIAL REPORT

A Randomized Double-Blind, Placebo-Controlled Study to Evaluate the Anti-Skin-Aging Effect of LactoSporin – The Extracellular Metabolite from Bacillus coagulans (Weizmannia coagulans) MTCC 5856 in Healthy Female Volunteers

, ORCID Icon, , & ORCID Icon
Pages 769-782 | Received 31 Jan 2023, Accepted 21 Mar 2023, Published online: 29 Mar 2023

Figures & data

Figure 1 Participant flow chart at each visit. A flow chart showing the activities carried out on each visit during the study. Open arrows: baseline, grey arrows: Week 5 and black arrows represent week 10.

Figure 1 Participant flow chart at each visit. A flow chart showing the activities carried out on each visit during the study. Open arrows: baseline, grey arrows: Week 5 and black arrows represent week 10.

Table 1 Baseline Demographics

Figure 2 Consort diagram.

Figure 2 Consort diagram.

Table 2 Dermatological Assessment of Facial Skin for Signs of Ageing

Table 3 Instrument Analysis of Facial Skin for Signs of Ageing

Figure 3 Analysis of topographical features of the skin by Antera 3D. Representative images from Antera 3D, showing the changes in crow’s feet, under-eye fine lines, nasolabial folds, and forehead fine lines in placebo and LactoSporin at baseline, week 5 and week 10. The blue marks represent wrinkles within the area of interest. A lower value indicates less severity and an improvement.

Figure 3 Analysis of topographical features of the skin by Antera 3D. Representative images from Antera 3D, showing the changes in crow’s feet, under-eye fine lines, nasolabial folds, and forehead fine lines in placebo and LactoSporin at baseline, week 5 and week 10. The blue marks represent wrinkles within the area of interest. A lower value indicates less severity and an improvement.

Figure 4 VISIA representative images. Representative VISIA images of two participants each from A -LactoSporin and B- Placebo group taken at baseline, week 5 and week 10. Full face digital images were taken using VISIA-CR Blue 4.3 Camera Imaging System on day 0, day 35 and at day 70 for all the participants. The representative VISIA images of two participants each from LactoSporin (A)and Placebo (B) taken at day 01, day 35 and day 70 are depicted.

Figure 4 VISIA representative images. Representative VISIA images of two participants each from A -LactoSporin and B- Placebo group taken at baseline, week 5 and week 10. Full face digital images were taken using VISIA-CR Blue 4.3 Camera Imaging System on day 0, day 35 and at day 70 for all the participants. The representative VISIA images of two participants each from LactoSporin (A)and Placebo (B) taken at day 01, day 35 and day 70 are depicted.

Table 4 Participant Response to Self-Assessment Questionnaire